Medmain is developing a marketplace for pathological image diagnosis, including Deep Learning based diagnosis.
Pathologists, a type of specialist medical practitioners who examine tissues of patients to make a final diagnosis, are required in any hospital. However, there is a shortage of them, and patients have to wait for a few weeks to obtain their results. We will solve this problem with “PidPort” and create a society where one can have a high-quality pathological diagnosis from any location.
Pathologists, a type of specialist medical practitioners who examine tissues of patients to make a final diagnosis, are required in any hospital. However, there is a shortage of them, and patients have to wait for a few weeks to obtain their results. We will solve this problem with “PidPort” and create a society where one can have a high-quality pathological diagnosis from any location.
Location: Japan, Minato
Total raised: $13.7M
Investors 2
| Date | Name | Website |
| - | Dogan Beta | dogan.vc/ |
| - | J-Startup | j-startup.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.05.2025 | - | $3.3M | - |
| 23.08.2020 | Series A | $10.4M | - |
Mentions in press and media 9
| Date | Title | Description |
| 09.05.2025 | Medmain Secures $3.3 Million to Revolutionize Digital Pathology | In the heart of Fukuoka, Japan, a medtech startup is making waves. Medmain Inc. has successfully raised $3.3 million in its latest funding round, bringing its total equity funding to an impressive $18 million. This infusion of capital is se... |
| 08.05.2025 | Medmain, a Japanese pathology AI startup, has raised 3.3M USD (total 18M USD), with investments from One Capital, Niremia Collective, and Plug and Play | FUKUOKA, Japan, May 8, 2025 /PRNewswire/ -- Medmain Inc., a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has raised 3.3 million USD through a third-p... |
| 08.05.2025 | Medmain Raises 3.3M USD in Funding | Medmain has rased 3.3M USD Medmain, a Fukuoka, Japan-based medtech startup providing an AI-powered cloud system, raised 3.3M USD in funding. The round was led by One Capital with participation from Niremia Collective and Plug and Play. The ... |
| 17.04.2024 | Medmain, a pathological AI developer, raises 850 million yen (total of 2.05 billion yen) in Series A2 round | Medmain, a pathological AI developer, raises 850 million yen (total of 2.05 billion yen) in Series A2 round *View in browser* *Medmain Co., Ltd.* Press release: April 18, 2024 ** Medmain, a pathological AI developer, raises 850 million yen ... |
| 17.04.2024 | Medmain, a pathological AI developer, raises 850 million yen (total of 2.05 billion yen) in Series A2 round | - |
| 02.11.2023 | 「久留米大学医学部」が教育・研究用途でデジタル病理支援クラウド「PidPort」を活用 | デジタル病理支援ソリューション「PidPort」を提供するメドメイン株式会社 ( 本社：福岡県福岡市、代表取締役CEO： 飯塚 統、以下「メドメイン」)は、教育および研究用途において、久留米大学様に「PidPort」を導入していただきましたことをお知らせいたします。 久留米大学医学部病理学講座様では、医学部生向けに実施されている病理学実習で、下記のような課題を感じており、今回PidPortを採用していただきました。 【教育用途】PidPortを導入した背景 ・顕微鏡を使... |
| 12.09.2023 | Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech | FUKUOKA, Japan, Sept. 12, 2023 /PRNewswire/ -- Medmain Inc. (https://en.medmain.com), a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has been selecte... |
| 16.03.2022 | Medmain Inc. Succeeded in developing pathological AI that accelerates cervical cancer screening with high accuracy-A paper published in Cancers (Cancers / Special issue: Artificial Intelligence in Onc... | Medmain Inc. Succeeded in developing pathological AI that accelerates cervical cancer screening with high accuracy-A paper published in Cancers (Cancers / Special issue: Artificial Intelligence in Oncology)- ……………………………………………………………………………………... |
| - | Medmain | “To create a world where medical services can be accessed with technology anywhere,anytime-As a supporting partner to medical practitioners throughout the world, Medmain develops and operates PidPort, an analytical system for pathological i... |